Download PDF
Open Access
CC BY-NC-ND 4.0 · J Lab Physicians 2016; 8(02): 096-100
DOI: 10.4103/0974-2727.180789
Original Article

Epidemiology of Rifampicin Resistant Tuberculosis and Common Mutations in rpoB Gene of Mycobacterium tuberculosis: A Retrospective Study from Six Districts of Punjab (India) Using Xpert MTB/RIF Assay

Authors

  • Ramandeep Kaur

    Department of Microbiology, Guru Gobind Singh Medical College, Faridkot, Punjab, India

  • Neerja Jindal

    Department of Microbiology, Guru Gobind Singh Medical College, Faridkot, Punjab, India

  • Shilpa Arora

    Department of Microbiology, Guru Gobind Singh Medical College, Faridkot, Punjab, India

  • Shajla Kataria

    Department of Microbiology, Guru Gobind Singh Medical College, Faridkot, Punjab, India

Financial support and sponsorship: Nil.
Further Information
Also available at
 PDF Download Permissions and Reprints

ABSTRACT

Background: Xpert MTB/RIF assay has revolutionized the diagnosis of tuberculosis (TB) by simultaneously detecting the bacteria and resistance to rifampicin (RIF), a surrogate marker for multidrug-resistant TB (MDR-TB) in <2 h. The RIF resistance pattern in Malwa region of Punjab, India, is not documented. Here, we report the epidemiology of RIF-resistant TB and mutations in rpoB gene of Mycobacterium tuberculosis (MTB).

Materials and Methods: A total of 1612 specimens received between October 2013 and February 2015 were tested by Xpert MTB/RIF assay following manufacturer’s instructions. The results thus obtained were analyzed using SPSS version 20.0.0 (SPSS Inc., Chicago, IL, USA) statistical software.

Result: RIF resistance was statistically higher in previously treated patients in comparison to the new patients (P = 0.006) and in patients with acid fast-Bacilli (AFB) positive smears to AFB-negative smears (P = 0.048). RIF resistance mutations in 130 specimens revealed frequency of E 73/130 (56%), B 28/130 (21.5%), D 18/130 (13.8%), A 11/130 (8.4%), and C 1/130 (0.7%) while in one specimen, mutation combination, i.e., mutations associated with more than one probe (A and B both) was present.

Conclusion: Xpert MTB/RIF assay is a user-friendly screening tool for detection of MTB and RIF resistance from suspected TB/MDR cases in a shorter period of time. It could also serve as a useful technique to have simultaneous preliminary information regarding the mutation pattern of RIF resistance in MTB isolates.

Key words:

Epidemiology - multidrug-resistant tuberculosis - Mycobacterium tuberculosis - rifampicin resistance determining region - Xpert MTB/RIF assay


Publication History

Article published online:
19 April 2020

© 2016.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • REFERENCES

  • 1 Kant S, Maurya AK, Kushwaha RA, Nag VL, Prasad R. Multi-drug resistant tuberculosis: An iatrogenic problem. Biosci Trends 2010;4:48-55.
  • 2 Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998;79:3-29.
  • 3 Purwar S, Chaudhari S, Katoch VM, Sampath A, Sharma P, Upadhyay P, et al. Determination of drug susceptibility patterns and genotypes of Mycobacterium tuberculosis isolates from Kanpur district, North India. Infect Genet Evol 2011;11:469-75.
  • 4 Geleta DA, Megerssa YC, Gudeta AN, Akalu GT, Debele MT, Tulu KD. Xpert MTB/RIF assay for diagnosis of pulmonary tuberculosis in sputum specimens in remote health care facility. BMC Microbiol 2015;15:220.
  • 5 Sekadde MP, Wobudeya E, Joloba ML, Ssengooba W, Kisembo H, Bakeera-Kitaka S, et al. Evaluation of the Xpert MTB/RIF test for the diagnosis of childhood pulmonary tuberculosis in Uganda: A cross-sectional diagnostic study. BMC Infect Dis 2013;13:133.
  • 6 El-Hajj HH, Marras SA, Tyagi S, Kramer FR, Alland D. Detection of rifampin resistance in Mycobacterium tuberculosis in a single tube with molecular beacons. J Clin Microbiol 2001;39:4131-7.
  • 7 World Health Organization. Global Tuberculosis Control: Epidemiology, Strategy, Financing. WHO Report 2009. Geneva: World Health Organization; 2009.
  • 8 Verma D, Malhotra B, Goyal S, Shah T, Gupta KN. Prevalence of MDR-TB and mutational pattern in rpoB gene of Mycobacterium tuberculosis at Eastern Rajasthan. Microcon 2014. (38th National Conference of Indian Association of Medical Microbiologist) MP39:253; 2014.
  • 9 Jain A, Diwakar P, Singh U. Declining trend of resistance to first-line anti-tubercular drugs in clinical isolates of Mycobacterium tuberculosis in a tertiary care North Indian hospital after implementation of revised national tuberculosis control programme. Indian J Med Microbiol 2014;32:430-3.
  • 10 Singhal R, Myneedu VP, Arora J, Singh N, Bhalla M, Verma A, et al. Early detection of multi-drug resistance and common mutations in Mycobacterium tuberculosis isolates from Delhi using GenoType MTBDRplus assay. Indian J Med Microbiol 2015;33 Suppl (1): 46-52.
  • 11 Desikan P, Chauhan DS, Sharma P, Panwalkar N, Yadav P, Ohri BS. Clonal diversity and drug resistance in Mycobacterium tuberculosis isolated from extra-pulmonary samples in central India - A pilot study. Indian J Med Microbiol 2014;32:434-7.
  • 12 Jain A, Diwakar P, Singh U. Declining trend of resistance to first-line anti-tubercular drugs in clinical isolates of Mycobacterium tuberculosis in a tertiary care north Indian hospital after implementation of revised national tuberculosis control programme. Indian J Med Microbiol 2014;32:430-3.
  • 13 TB India 2012, Annual Status Report Government of India; 2012. Available from: http://www.tbcindia.com. [Last accessed on 2015 Jul 12].
  • 14 Gupta A, Nagaraja MR, Kumari P, Singh G, Raman R, Singh SK, et al. Association of MDR-TB isolates with clinical characteristics of patients from Northern region of India. Indian J Med Microbiol 2014;32:270-6.
  • 15 Quy HT, Cobelens FG, Lan NT, Buu TN, Lambregts CS, Borgdorff MW. Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis 2006;10:45-51.
  • 16 Mboowa G, Namaganda C, Ssengooba W. Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert® MTB/RIF in Kampala, Uganda: A retrospective study. BMC Infect Dis 2014;14:481.
  • 17 Rufai SB, Singh A, Kumar P, Singh J, Singh S. Performance of Xpert MTB/RIF assay in diagnosis of pleural tuberculosis by use of pleural fluid samples. J Clin Microbiol 2015;53:3636-8.
  • 18 Nwokoye N, Onubogu C, Nwadike O, Abiodun A, Onwujekwe D, Gidado M, et al. Non-conforming rifampicin susceptibility test reports from Xpert MTB/RIF assay: The national reference laboratory experience in Nigeria. Open Sci J Clin Med 2014;2:59-62.
  • 19 Mani C, Selvakumar N, Narayanan S, Narayanan PR. Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis clinical isolates from India. J Clin Microbiol 2001;39:2987-90.
  • 20 Billington OJ, McHugh TD, Gillespie SH. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999;43:1866-9.